PD-1 inhibitors (Programmed Cell Death Protein 1 Inhibitor) enhance T-cell-mediated anti-tumor immune responses by blocking the PD-1/PD-L1 pathway (9). This evidence concerns the gene PDCD1 and neoplasm.